Data gathered: July 5
AI Stock Analysis - Mannkind (MNKD)
Analysis generated September 9, 2024. Powered by Chat GPT.
Mannkind Corporation is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. The company is especially known for its rapid-acting insulin, Afrezza, which is widely used to treat diabetes. Mannkind’s commitment to innovation and patient care has helped it carve out a niche within the competitive biopharmaceutical sector.
Stock Alerts - Mannkind (MNKD)
 |
Mannkind | June 25 Price is down by -7% in the last 24h. |
|
Mannkind | June 11 Insider Alert: Binder Steven B. is selling shares |
|
Mannkind | June 10 Price is down by -10.1% in the last 24h. |
|
Mannkind | May 21 Insider Alert: Thomson David is selling shares |
Download our app to get future alerts delivered in real-time.
Alternative Data for Mannkind
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 27 | Sign up | Sign up | Sign up |
| Sentiment | 80 | Sign up | Sign up | Sign up |
| Webpage traffic | 7,000 | Sign up | Sign up | Sign up |
| Employee Rating | 74 | Sign up | Sign up | Sign up |
| Google Trends | 21 | Sign up | Sign up | Sign up |
| Patents | 117 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 40 | Sign up | Sign up | Sign up |
| Facebook Followers | 1,490 | Sign up | Sign up | Sign up |
| Instagram Followers | 1,216 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 345 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 40,987 | Sign up | Sign up | Sign up |
| Twitter Followers | 2,783 | Sign up | Sign up | Sign up |
| Twitter Mentions | 24 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 272 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 82 | Sign up | Sign up | Sign up |
| Linkedin Employees | 600 | Sign up | Sign up | Sign up |
About Mannkind
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States.
| Price | $3.60 |
| Target Price | Sign up |
| Volume | 1,730,000 |
| Market Cap | $1.09B |
| Year Range | $3.58 - $7.44 |
| Dividend Yield | 0% |
| PE Ratio | 36 |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
MannKind Corporation(NasdaqGM: MNKD) dropped from Russell 3000E IndexJune 29 - Finnhub |
|
MannKind Corporation(NasdaqGM: MNKD) dropped from Russell Microcap IndexJune 29 - Finnhub |
|
MannKind Corporation(NasdaqGM: MNKD) dropped from Russell Microcap Growth IndexJune 29 - Finnhub |
|
MannKind Corporation(NasdaqGM: MNKD) dropped from Russell 3000E Growth IndexJune 29 - Finnhub |
|
MannKind Corporation(NasdaqGM: MNKD) dropped from Russell Microcap Value IndexJune 29 - Finnhub |
|
MannKind Corporation(NasdaqGM: MNKD) dropped from Russell 3000E Value IndexJune 29 - Finnhub |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 78M | 18M | 61M | 13M | 0 | 0.040 |
| Q4 '24 | 77M | 20M | 57M | 7.4M | 19M | 0.026 |
| Q3 '24 | 70M | 18M | 52M | 12M | 13M | 0.050 |
| Q2 '24 | 72M | 20M | 52M | -2M | 18M | -0.010 |
| Q1 '24 | 66M | 19M | 48M | 11M | 17M | 0.040 |
Insider Transactions View All
| Binder Steven B. filed to sell 925,258 shares at $4. June 10 '25 |
| Thomson David filed to sell 879,546 shares at $4.4. May 20 '25 |
| Binder Steven B. filed to sell 989,343 shares at $4.4. May 20 '25 |
| Binder Steven B. filed to sell 1,006,611 shares at $4.7. May 15 '25 |
| Thomson David filed to sell 772,427 shares at $4.7. May 15 '25 |
Similar companies
Read more about Mannkind (MNKD) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Mannkind?
The Market Cap of Mannkind is $1.09B.
What is Mannkind's PE Ratio?
As of today, Mannkind's PE (Price to Earnings) ratio is 36.
What is the current stock price of Mannkind?
Currently, the price of one share of Mannkind stock is $3.60.
How can I analyze the MNKD stock price chart for investment decisions?
The MNKD stock price chart above provides a comprehensive visual representation of Mannkind's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Mannkind shares. Our platform offers an up-to-date MNKD stock price chart, along with technical data analysis and alternative data insights.
Does MNKD offer dividends to its shareholders?
As of our latest update, Mannkind (MNKD) does not offer dividends to its shareholders. Investors interested in Mannkind should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Mannkind?
Some of the similar stocks of Mannkind are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.